Tesamorelin

A stabilised GHRH analogue best known in research for reducing stubborn visceral fat while supporting the growth-hormone axis.

What it is

Tesamorelin is a stabilised, full-length GHRH analogue. Among growth-hormone peptides it stands out for having the strongest clinical evidence base, having been studied formally for visceral fat reduction.

How it's thought to work

It stimulates the pituitary to release growth hormone, which in turn raises IGF-1 and influences fat metabolism. Its most notable research effect is a reduction in visceral adipose tissue — the metabolically active fat around the organs.

Potential health benefits

Investigated for:

Reducing visceral abdominal fat.
Improving body composition overall.
Favourable shifts in some lipid markers.

What the research says

Tesamorelin has been through controlled human trials in specific clinical populations, where it consistently lowered visceral fat. That gives it more robust human data than most peptides on this site, though general-wellness use is still off-label and research-grade.

Considerations

A research compound for general use. Discuss with a qualified clinician, especially if you have metabolic or cardiovascular conditions.